Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Fish and Richardson
Healthtrust
Dow
Johnson and Johnson
Fuji
Baxter
Express Scripts
Chinese Patent Office
Farmers Insurance

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,004,968

« Back to Dashboard

Which drugs does patent 6,004,968 protect, and when does it expire?

Patent 6,004,968 protects EPIVIR and EPIVIR-HBV and is included in two NDAs.

Protection for EPIVIR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-four patent family members in forty-three countries.
Summary for Patent: 6,004,968
Title: Pharmaceutical compositions containing lamivudine
Abstract:The present invention relates to pharmaceutical formulations containing (2R, cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2 -one (-)-2',3'-dideoxy,3'-thiacytidine, lamivudine, that are substantially free of ethanol and ethylenediamine-tetraacitic acid, and their use in medical therapy.
Inventor(s): Casey; Warren Michael (Knightdale, NC), Nguyen; Ngoc-Anh Thi (Durham, NC)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:09/044,896
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Drugs Protected by US Patent 6,004,968

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Viiv Hlthcare EPIVIR lamivudine SOLUTION;ORAL 020596-001 Nov 17, 1995 AA RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Glaxosmithkline EPIVIR-HBV lamivudine SOLUTION;ORAL 021004-001 Dec 8, 1998 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,004,968

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9706295Mar 26, 1997

International Patents Family Members for US Patent 6,004,968

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 1255849 ➤ Sign Up
China 1191061 ➤ Sign Up
Argentina 011697 ➤ Sign Up
Austria 295150 ➤ Sign Up
Australia 7208498 ➤ Sign Up
Australia 728461 ➤ Sign Up
Colombia 4980849 ➤ Sign Up
Cyprus 2569 ➤ Sign Up
Czech Republic 298008 ➤ Sign Up
Czech Republic 9903403 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
McKinsey
Fish and Richardson
AstraZeneca
Mallinckrodt
Dow
Julphar
Teva
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot